Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
QURE logo QURE
Upturn stock ratingUpturn stock rating
QURE logo

Uniqure NV (QURE)

Upturn stock ratingUpturn stock rating
$13.94
Last Close (24-hour delay)
Profit since last BUY-4.47%
upturn advisory
SELL
SELL since 4 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: QURE (1-star) is a SELL. SELL since 4 days. Profits (-4.47%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

13 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $36.51

1 Year Target Price $36.51

Analysts Price Target For last 52 week
$36.51Target price
Low$3.73
Current$13.94
high$19.18

Analysis of Past Performance

Type Stock
Historic Profit -57.45%
Avg. Invested days 21
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 765.93M USD
Price to earnings Ratio -
1Y Target Price 36.51
Price to earnings Ratio -
1Y Target Price 36.51
Volume (30-day avg) 13
Beta 0.09
52 Weeks Range 3.73 - 19.18
Updated Date 07/1/2025
52 Weeks Range 3.73 - 19.18
Updated Date 07/1/2025
Dividends yield (FY) -
Basic EPS (TTM) -4.38

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-06-18
When Before Market
Estimate -0.8863
Actual -0.7278

Profitability

Profit Margin -
Operating Margin (TTM) -2815.25%

Management Effectiveness

Return on Assets (TTM) -15.64%
Return on Equity (TTM) -241.16%

Valuation

Trailing PE -
Forward PE 27.93
Enterprise Value 420379034
Price to Sales(TTM) 37.92
Enterprise Value 420379034
Price to Sales(TTM) 37.92
Enterprise Value to Revenue 20.81
Enterprise Value to EBITDA 0.99
Shares Outstanding 54748500
Shares Floating 35512064
Shares Outstanding 54748500
Shares Floating 35512064
Percent Insiders 6.09
Percent Institutions 91.95

Analyst Ratings

Rating 3
Target Price 36.51
Buy 2
Strong Buy 9
Buy 2
Strong Buy 9
Hold 2
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Uniqure NV

stock logo

Company Overview

overview logo History and Background

uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, Netherlands. It is a pioneer in gene therapy, focusing on developing and commercializing transformative genetic medicines for patients with severe unmet medical needs. Initially focused on cardiovascular disease, the company shifted its focus to liver-directed gene therapies.

business area logo Core Business Areas

  • Liver-Directed Gene Therapies: uniQure's primary focus is on developing gene therapies targeting the liver, where genetic modifications can have a significant impact on systemic diseases.
  • Neurological Disorders: uniQure is also developing gene therapies for neurological disorders.

leadership logo Leadership and Structure

uniQure is led by a management team with expertise in gene therapy and biotechnology. The company has a board of directors overseeing its strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • Hemgenix (etranacogene dezaparvovec): Hemgenix is a gene therapy approved for the treatment of hemophilia B in adults. It is a one-time infusion designed to provide long-term factor IX expression, reducing the need for prophylactic treatment. CSL Behring is a competitor in this area.
  • AMT-130: AMT-130 is an AAV5 gene therapy under investigation for the treatment of Huntington's disease. Currently in clinical trials, aiming to reduce the mutant Huntingtin protein, addressing the underlying genetic cause of the disease. WAVE Life Sciences and Roche are competitors in this area.

Market Dynamics

industry overview logo Industry Overview

The gene therapy industry is rapidly evolving, with significant advancements in vector technology, gene editing, and delivery methods. The market is driven by the potential for curative therapies for genetic diseases.

Positioning

uniQure is a pioneer in gene therapy, focusing on liver-directed gene therapies and neurological disorders. Their competitive advantage lies in their experience, proprietary technology platforms, and clinical expertise.

Total Addressable Market (TAM)

The TAM for gene therapies is estimated to reach billions of dollars in the coming years. uniQure is well-positioned to capture a significant share of this market with its established pipeline and approved product.

Upturn SWOT Analysis

Strengths

  • Pioneering gene therapy platform
  • Approved product (Hemgenix)
  • Strong pipeline of gene therapy candidates
  • Experienced management team
  • Proprietary AAV vector technology

Weaknesses

  • High development costs
  • Regulatory hurdles
  • Manufacturing complexities
  • Reliance on clinical trial success
  • Commercialization challenges

Opportunities

  • Expanding into new therapeutic areas
  • Developing new gene therapy technologies
  • Partnering with pharmaceutical companies
  • Acquiring complementary technologies
  • Expanding global reach

Threats

  • Competition from other gene therapy companies
  • Regulatory setbacks
  • Manufacturing disruptions
  • Clinical trial failures
  • Pricing and reimbursement pressures

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • VRTX
  • CRSP

Competitive Landscape

uniQure faces competition from established pharmaceutical companies and other gene therapy developers. Its advantages include its proprietary technology and focus on liver-directed gene therapies.

Major Acquisitions

InoCell B.V.

  • Year: 2013
  • Acquisition Price (USD millions): 28.4
  • Strategic Rationale: Enhanced manufacturing capabilities and process development expertise in cell-based therapies.

Growth Trajectory and Initiatives

Historical Growth: uniQure's historical growth has been driven by the advancement of its gene therapy pipeline and partnerships.

Future Projections: Future growth is projected to be driven by Hemgenix sales, clinical trial successes, and new product launches. Analyst estimates vary based on specific assumptions.

Recent Initiatives: Recent initiatives include advancing clinical trials for AMT-130 and other gene therapy candidates, as well as expanding manufacturing capacity.

Summary

uniQure is a pioneering gene therapy company with an approved product, Hemgenix. The high cost of gene therapy development and regulatory complexities are challenges. Success hinges on clinical trial outcomes and strategic partnerships. uniQure is positioned to capitalize on the growth of the gene therapy market.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications
  • Company Website

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Uniqure NV

Exchange NASDAQ
Headquaters -
IPO Launch date 2007-06-20
CEO & Executive Director Mr. Matthew Craig Kapusta CPA
Sector Healthcare
Industry Biotechnology
Full time employees 209
Full time employees 209

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.